Charles Swanton
Charles Swanton - A test that uses tumour DNA from the blood of patients with cancer, to predict if the disease will return after surgery, was developed by the TRACERx team led by UCL's Professor Charles Swanton. Here, following the test's validation in a clinical trial, he explains its journey. Caring for patients with cancer can be incredibly rewarding. We've seen amazing progress in recent years, with new tests and therapies that enable us to successfully treat and manage the disease for more people. But significant challenges remain. Tumours evolve over time, adapting to their surroundings, becoming resistant to treatments and spreading to other parts of the body. We and others have reasoned that the earlier disease relapse can be detected, the smaller the burden of disease and the greater the chance that treatments will be effective.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
